Increased death, disability, dementia linked to poststroke seizures
By
Kristen Fischer
Sep 26, 2023
When a person has a seizure after a stroke — something known as a poststroke seizure, or PSS — it’s linked to a higher risk for poorer outcomes, disability, dementia and death, according to a new...
Dementia decline could be slowed by antiseizure meds in some cases, study finds
By
Alicia Lasek
Dec 05, 2022
The results revealed profound early decline among dementia patients with active seizures, including worse cognitive and mental health, and daily functioning.
Electrocardiography should be considered for nocturnal enuresis
Apr 13, 2022
Survey of physicians finds that only 1.1% proposed performing ECG in case of unexplained nocturnal enuresis episodes
Clinical briefs for Friday, Oct 1
By
Alicia Lasek
Oct 01, 2021
REGEN-COV antibody treatment cuts severe COVID risk at half dose, late-stage trial results show … Drug improves memory and function for those with dementia and ‘silent seizures’ … Depression relapse...
Trio is trouble in assisted living: Risky neuro drug combos too common, dementia expert says
By
Alicia Lasek
Mar 11, 2021
Fully one in seven people with dementia who do not live in nursing homes are taking at least three drugs that act on the central nervous system — beyond the advised limit, a new study finds.
Clinical Briefs for Friday, May 8
By
Alicia Lasek
May 07, 2020
Lab cautions nursing homes about inaccurate coronavirus test kits … HCR ManorCare: 70% of COVID-19 infected employees asymptomatic … Nurse survey finds No.1 concern is infecting others, 38% reassigned...
Clinical Briefs for Wednesday, December 11
By
Alicia Lasek
Dec 10, 2019
Inflammatory marker linked to dementia … Duration of diabetes history tied to higher short-term mortality risk … New drug reduces seizures in epilepsy type common among seniors … Narcissism declines...
Residents with Alzheimer’s far more likely to experience recurring epileptic seizures
By
Alicia Lasek
Jul 20, 2019
People with Alzheimer’s disease experience epileptic seizures up to five times more often than those without dementia, new research has found.
Abbott Labs wrongly pushed Depakote for dementia care, will pay $1.5 billion
By
McKnight's Staff
May 07, 2012
Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.